drugset / Trial / NCT06254807
CAR-monocytes for the Treatment of HER2 Overexpressing Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is a first-in-human open-label study to evaluate the safety and tolerability, and manufacturing feasibility of anti-HER2 CAR-monocytes (CT-0525) in participants with locally advanced (unresectable) or metastatic solid tumors overexpressing HER2 whose disease has progressed on standard approved therapies.
Timeline
- Start
- 2024-01-08
- Primary completion
- 2025-03-31
- Completion
- 2026-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CT-0525 | Cell therapy | 3e+09 cells | Intravenous |
| Subject | CT-0525 | Cell therapy | 1e+10 cells | Intravenous |
Indications
No indication recorded.